The group's principal activity is to discover, develop and market proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by current pain treatments. The group is in the development stage. The group has a portfolio of small molecule product candidates that are in various stages of development ranging from pre-clinical studies to phase i through phase iii clinical trials. Its product candidate, alvimopan, also known as adl 8-2698, is designed to selectively block the effects of narcotic analgesics on the gastrointestinal tract. It has obtained licenses from kwang dong pharmaceutical co ltd and santen pharmaceutical co ltd of Japan to develop and market dermal formulations of adl 2-1294 in South Korea and north Korea for dermal pain and ophthalmic pain respectively.
Executive Information
Name
Title
Email
David Madden
Chmn.
N/A
James Barrett
Sr. VP, Chief Scientific Officer, Pres. - Research
